A Phase 1/2 Study of Bleximenib in Participants with Acute Leukemia (cAMeLot-1)
Clinical Trial Grant
Awarded By
Janssen Research & Development, LLC
Start Date
April 21, 2026
End Date
September 29, 2026
Awarded By
Janssen Research & Development, LLC
Start Date
April 21, 2026
End Date
September 29, 2026